PET-Probe: Evaluation of technical performance and clinical utility of a handheld high-energy gamma probe in oncologic surgery

Annals of Surgical Oncology

Volumn 23, Issue , 2016, Pages 9020-9027

  Gulec, Seza A ^a   Daghighian, Farhad ^b   Essner, Richard ^c  

^a Goshen Health System Center for Cancer Care   (United States)

^b IntraMedical Imaging LLC   (United States)

^c JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

Gamma probe; PET FDG; PET Probe; Radioguided surgery

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER OF UNKNOWN PRIMARY SITE; CANCER PATIENT; CLINICAL ARTICLE; COLON CANCER; FEMALE; HANDHELD HIGH ENERGY GAMMA PROBE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LYMPHOMA; MALE; MELANOMA; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE STUDY; SARCOIDOSIS; SEMINOMA; SURGICAL EQUIPMENT; SURGICAL ONCOLOGY; SURGICAL PATIENT; THYROID CANCER; TUMOR VOLUME; WHOLE BODY PET; ADOLESCENT; DEVICES; DIAGNOSTIC IMAGING; EVALUATION STUDY; GAMMA RADIATION; INTRAOPERATIVE PERIOD; MIDDLE AGED; NEOPLASM; PATHOLOGY; PROCEDURES; RADIOMETRY; TUMOR RECURRENCE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; GAMMA RAYS; HUMANS; INTRAOPERATIVE PERIOD; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOMETRY; RADIOPHARMACEUTICALS; YOUNG ADULT;

EID: 84855780456     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/ASO.2006.05.047     Document Type: Article

References (39)

1. Selverstone B, Sweet WH, Robinson CV. The clinical use of radioactive phosphorus in the surgery of brain tumors. Ann Surg 1949; 130:643-51.
2. Morris AC, Barclay TR, Tanida R, Nemcek JV. A miniaturized probe for detecting radioactivity at thyroid surgery. Physics Med Biol 1971; 16:397-404.
3. Knoll GF, Lieberman LM, Nishiyama H, Bierwaltes WH. A gamma ray probe for the detection of ocular melanomas. IEEE Trans Nucl Sci 1972; NS-19:76-80.
4. Kuhn JA, Corbisiero RM, Buras RR, et al. Intraoperative gamma detection probe with presurgical antibody imaging in colon cancer. Arch Surg 1991; 126:1398-403.
5. Arnold MW, Schneebaum S, Berens A, et al. Intraoperative detection of colorectal cancer with radioimmunoguided surgery and CC49, a second-generation monoclonal antibody. Ann Surg 1992; 216:627-32.
6. Gulec SA, Serafini AN, Moffat FL, et al. Radioimmunoscintigraphy of colorectal carcinoma using technetium-99m labeled, totally human monoclonal antibody 88BV59H21-2. Cancer Res 1995; 55(Suppl):5774-6.
7. Moffat FL, Vargas-Cuba RD, Serafini AN, et al. Preoperative scintigraphy and operative probe scintimetry of colorectal carcinoma using technetium-99m-88BV59. J Nucl Med 1995; 36:738-45.
8. Alex JC, Krag BN. Gamma-probe guided localization of lymph nodes. Surg Oncol 1993; 2:137-43.
9. Krag DN, Meijer SJ, Weaver DL, et al. Minimal-access surgery for staging of malignant melanoma. Arch Surg 1995; 130:654-60.
10. Krag DN, Weaver DL, Alex JC, et al. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 1993; 2:335-40.
11. Gulec SA, Moffat FL, Carroll RG, et al. Sentinel node localization in early breast cancer. J Nucl Med 1998; 39:1388-93.
12. Gulec SA, Moffat FL, Carroll RG, Krag DN. Gamma probe-guided sentinel node biopsy in breast cancer. Q J Nucl Med 1997; 41:251-61.
13. Bozkurt F, Ugur O, Hamaloglu E, Sayek I, Gulec SA. Optimization of gamma probe-guided parathyroidectomy. Am Surg 2003; 69:720-5.
14. Mariani G, Gulec SA, Rubello D, et al. Preoperative localization and radioguided parathyroid surgery. J Nucl Med 2003; 44:1443-58.
15. Schirmer WJ, Odorisio TM, Schirmer TP, et al. Intraoper ative localization of neuroendocrine tumors with 125I-TYR(3)-octreotide and a hand held gamma-detecting probe. Surgery 1993; 114:745-52.
16. Ahlman H, Tisell L-E, Wangberg B, et al. Somatostatin receptors on neuroendocrine tumors-a way to intraoperative diagnosis and localization. Yale J Biol Med 1995; 67:215-21.
17. Vanstee nkiste J, Fischer BM, Dooms C, Mortensen J. Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncol 2004; 5:531-40.
18. Burton C, Ell P, Linch D. The role of PET imaging in lymphoma. Br J Haematol 2004; 126:772-84.
19. Siggelkow W, Rath W, Buell U, Zimny M. FDG PET and tumour markers in the diagnosis of recurrent and metastatic breast cancer. Eur J Nucl Med Mol Imaging 2004; 31(Suppl 1):S118-24.
20. van Westreenen HL, Westerterp M, Bossuyt PM, et al. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol 2004; 22:3805-12.
21. Gulec SA, Faries MB, Lee CC, Glass E, Morton DL, Essner R. The role of FDG-PET in the management of patients with metastatic melanoma: impact on surgical decision making. Clin Nucl Med 2003; 28:961-5.
22. Wiering B, Ruers TJ, Oyen WJ. Role of FDG-PET in the diagnosis and treatment of colorectal liver metastases. Expert Rev Anticancer Ther 2004; 4:607-13.
23. Hustinx R. PET imaging in assessing gastrointestinal tumors. Radiol Clin North Am 2004; 42:1123-39.
24. Weber WA, Ott K. Imaging of esophageal and gastric cancer. Semin Oncol 2004; 31:530-41.
25. de Groot JW, Links TP, Jager PL, Kahraman T, Plukker JT. Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol 2004; 11:786-94.
26. Wang W, Larson SM, Fazzari M, et al. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 2000; 85:1107-13.
27. Kumar R, Alavi A. PET imaging in gynecologic malignancies. Radiol Clin North Am 2004; 4:1155-67.
28. Performance Measurements and Quality Control Guidelines for Non-Imaging Intraoperative Gamma Probes (NEMA Standards Publication NU 3-2004). National Electrical Manufacturers Association. Rosslyn, Virginia: Nema, 2004.
29. Moffat FL Jr, Gulec SA, Sittler SY, et al. Unfiltered sulfur colloid and sentinel node biopsy for breast cancer: technical and kinetic considerations. Ann Surg Oncol 1999; 6:746-55.
30. Ross GL, Soutar DS, Gordon MacDonald D, et al. Sentinel node biopsy in head and neck cancer.Prelimin ary results of a multicenter trial. Ann Surg Oncol 2004; 11:690-6.
31. Gulec SA, Moffat FL, Carroll RG. The expanding clinical role for intraoperative gamma probes. Nucl Med Ann 1997;: 209-37.
32. Zanzonico P, Heller S. The intraoperative gamma probe: basic principles and choices available. Semin Nucl Med 2000; 30:33-48.
33. Perkins AC, Britten AJ. Specification and performance of intra-operative gamma probes for sentinel node detection. Nucl Med Commun 1999; 20:309-15.
34. Hoffman EJ, Tornai MP, Janecek M, et al. Intraoperative probes and imaging probes. Eur J Nucl Med 1999; 26:913-35.
35. Essner R, Hsueh EC, Haigh PI, et al. Application of an [18F] fluorodeoxyglucose-sensitive probe for the intraoperative detection of malignancy. J Surg Res 2001; 96:120-6.
36. Boerner AR, Weckesser M, Herzog H, et al. Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer. Eur J Nucl Med 1999; 26:226-30.
37. Hsueh EC, Essner R, Foshag LJ, et al. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol 2002; 20:4549-54.
38. Fuzun M, Terzi C, Sokmen S, et al. Potentially curative resection for locoregional recurrence of colorectal cancer. Surg Today 2004; 34:907-12.
39. Cobben DC, Jager PL, Elsinga PH, et al. 3′-18F-fluoro-3′-deoxy-L-thymidine: A new tracer for staging metastatic melanoma? J Nucl Med 2003; 44:1927-32.